PMS premenstrual syndrome Asian woman holding head in pain having headache, stomach cramps, acne, mood swings with symptoms written on blackboard background in chalk.
DUBLIN, Ireland, Feb. 20, 2020 /CNW/ – Health and wellness company Satipharm Ltd. (“Satipharm” or the “Company”) has initiated clinical research into the use of CBD for relief from menopause symptoms. Following the successful completion of its Phase II clinical trial demonstrating that Satipharm CBD capsules reduced seizures in children with treatment-resistant epilepsy by an average 73%, the company is now turning its attention to perimenopause and menopause.
Utilizing Satipharm’s Advanced CBD capsules with Gelpell® delivery technology, manufactured under Good Manufacturing Practice (“GMP”), the aim of the clinical research is to demonstrate that Satipharm’s patented CBD formulation will provide significant relief from symptoms associated with these physiological changes.
Jonathan Hartshorn, CEO of Satipharm, commented “providing clinical evidence to our customers, on which they can base their health decisions, is a priority focus for Satipharm. Following the success of our Phase II clinical trial in epilepsy, we have been identifying new areas of research to advance the understanding of CBD. We are seeing increasing evidence that CBD is beneficial to women seeking relief from perimenopausal and menopausal symptoms which warrants further clinical investigation.”
Perimenopause for most women starts between the ages of 42 – 52, and can cause a number of undesirable symptoms, including:
- irregular menstrual cycles
- hot flushes
- night sweats
- fatigue
- sleep issues
- mood swings
Visit CannapyHealth.com for all your CBD needs